Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $405.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 123.60% from the stock’s previous close.
A number of other equities analysts have also recently commented on the company. Chardan Capital restated a “buy” rating and set a $250.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, August 8th. Stifel Nicolaus reiterated a “buy” rating and issued a $240.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday. Sanford C. Bernstein decreased their price objective on Alnylam Pharmaceuticals from $247.00 to $233.00 in a research note on Wednesday, July 26th. Morgan Stanley reiterated an “equal weight” rating and issued a $210.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, August 4th. Finally, StockNews.com assumed coverage on Alnylam Pharmaceuticals in a research note on Thursday, August 17th. They issued a “hold” rating for the company. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $247.40.
Alnylam Pharmaceuticals Stock Performance
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.49). Alnylam Pharmaceuticals had a negative net margin of 85.95% and a negative return on equity of 1,287.80%. The firm had revenue of $318.75 million for the quarter, compared to analysts’ expectations of $331.73 million. As a group, equities analysts predict that Alnylam Pharmaceuticals will post -6.79 earnings per share for the current fiscal year.
Insider Buying and Selling at Alnylam Pharmaceuticals
In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 4,166 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $183.89, for a total value of $766,085.74. Following the transaction, the chief marketing officer now directly owns 4,345 shares in the company, valued at approximately $799,002.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CMO Pushkal Garg sold 4,166 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $183.89, for a total value of $766,085.74. Following the sale, the chief marketing officer now directly owns 4,345 shares in the company, valued at $799,002.05. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Jeffrey V. Poulton sold 3,460 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $185.85, for a total value of $643,041.00. Following the completion of the sale, the chief financial officer now owns 15,873 shares in the company, valued at $2,949,997.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,144 shares of company stock worth $2,806,347. 1.40% of the stock is currently owned by insiders.
Institutional Trading of Alnylam Pharmaceuticals
Institutional investors have recently modified their holdings of the business. Norges Bank purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $240,703,000. Capital International Investors boosted its position in Alnylam Pharmaceuticals by 29.2% during the second quarter. Capital International Investors now owns 2,880,643 shares of the biopharmaceutical company’s stock worth $547,152,000 after purchasing an additional 651,054 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Alnylam Pharmaceuticals by 9.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,074,144 shares of the biopharmaceutical company’s stock worth $968,221,000 after purchasing an additional 353,538 shares in the last quarter. Eaton Vance Management raised its holdings in shares of Alnylam Pharmaceuticals by 606.7% in the first quarter. Eaton Vance Management now owns 306,228 shares of the biopharmaceutical company’s stock worth $50,005,000 after acquiring an additional 262,893 shares during the last quarter. Finally, Natixis raised its holdings in shares of Alnylam Pharmaceuticals by 105.5% in the fourth quarter. Natixis now owns 464,510 shares of the biopharmaceutical company’s stock worth $109,754,000 after acquiring an additional 238,476 shares during the last quarter. 93.98% of the stock is currently owned by hedge funds and other institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
- Five stocks we like better than Alnylam Pharmaceuticals
- The 3 Best Retail Stocks to Shop for in August
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- Most Active Stocks: Dollar Volume vs Share Volume
- 5 Reasons Mullen Automotive is About to Turn a Corner
- 3 Tickers Leading a Meme Stock Revival
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.